Second-generation antisense drug for prostate cancer.
Kerr
Cathel
C
D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002986:Clinical Trials as Topic; D051152:Clusterin; D003169:Complement Inactivator Proteins; D006023:Glycoproteins; D006207:Half-Life; D006801:Humans; D008297:Male; D018832:Molecular Chaperones; D016376:Oligonucleotides, Antisense / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; C495242:CLU protein, human; D051152:Clusterin; D003169:Complement Inactivator Proteins; D006023:Glycoproteins; D018832:Molecular Chaperones; D016376:Oligonucleotides, Antisense